Google Übersetzer
Travere Therapeutics, Inc.
About
47.76USD+3.47 +7.83%
Closed • Updated at 04:18 GMT+00:00Market Cap$4.44B
Volume3.11M
Beta2.14
RSI69.87
Gross Margin84.94%
Travere Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
May 7 2026
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 5 2026
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 4 2026
Travere Therapeutics Reports First Quarter 2026 Financial Results
Apr 27 2026
Travere Therapeutics to Report First Quarter 2026 Financial Results
Recent Videos
Travere (TVTX) Stock: The Massive 2026 FDA Milestone Nobody is Talking About!
May 12, 2026
Travere Therapeutics: From Orphan Drug Pioneer to Rare Disease Powerhouse - $TVTX
May 11, 2026
Travere Therapeutics Inc Chart Analysis - Options Trading Charts
May 05, 2026
Developments in FSGS: Biology, Proteinuria Reduction, and Clinical Evidence
Apr 28, 2026
Community Chat
Ask AI
Try asking